MedTrace Logo

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

NCT02314208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-02

No results posted yet for this study

Summary

The purpose of this project is to study the efficacy of three candidate molecules (Xenbilox, Tahor and Resveratrol) in order to decrease the production of oxysterols by reducing the synthesis of cholesterol and/or regulate the production of bile acids and/or enabling neuroprotective action within the motor neuron.

Conditions

  • Spastic Paraplegia, Hereditary

Interventions

DRUG

Xenbilox

DIETARY_SUPPLEMENT

Resveratrol

DRUG

Tahor

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Fanny MOCHEL, MD-PhD · Pitié-Salpêtrière Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-08
Primary Completion
2017-09-27
Completion
2018-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314208 on ClinicalTrials.gov